Printed from Voxsanity (voxsanity.com.au) — NCT06878261 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People aged 40 to 80 years old
People who have been diagnosed with COPD for at least 1 year
People whose lung function test results fall within a specific range, showing moderate-to-severe airflow limitation (confirm exact values with trial site)
People who have been taking either triple inhaled COPD therapy (three types of inhalers combined) or dual inhaled therapy, if triple therapy was not considered suitable, for at least 3 months in a row before the first visit
People who have had at least 2 moderate COPD flare-ups, or at least 1 severe flare-up, in the past year — where at least one moderate flare-up required treatment with steroid tablets or injections, and at least one flare-up happened while the person was already on their inhaler maintenance therapy
People whose blood test during screening shows a certain type of immune cell (eosinophils) at 150 cells per microlitre or higher
People whose COPD symptom score (CAT score) is 15 or higher at screening
People who are current or former smokers with a smoking history of at least 10 pack-years (a measure of how much someone has smoked over their lifetime)
Who may not be able to join:
People who have another significant lung disease, or whose chest imaging suggests a respiratory condition other than COPD
People who have asthma (including a history of childhood asthma) or a combined asthma-COPD condition
People who have any unstable health condition that could affect their safety or the results of the study
People who have needed treatment for tuberculosis within the 12 months before their second study visit
People who currently have, or have previously had, a cancer diagnosis
People who have been taking macrolide antibiotics for less than 6 months (confirm with trial site)
People who are taking medications that suppress or alter the immune system
People who require high-flow long-term oxygen therapy above 4 litres per minute, or whose blood oxygen levels remain too low even while on long-term oxygen therapy
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: MeiLan Han, MD, University of Michigan Health, Pulmonary & Critical Care Medicine,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06878261
Sponsor: AstraZeneca
Phase: Phase 3
Status: Recruiting
Condition: COPD
Trial contact: 1-877-240-9479
More information: https://clinicaltrials.gov/study/NCT06878261
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People aged 40 to 80 years old
People who have been diagnosed with COPD for at least 1 year
People whose lung function test results fall within a specific range, showing moderate-to-severe airflow limitation (confirm exact values with trial site)
People who have been taking either triple inhaled COPD therapy (three types of inhalers combined) or dual inhaled therapy, if triple therapy was not considered suitable, for at least 3 months in a row before the first visit
People who have had at least 2 moderate COPD flare-ups, or at least 1 severe flare-up, in the past year — where at least one moderate flare-up required treatment with steroid tablets or injections, and at least one flare-up happened while the person was already on their inhaler maintenance therapy
People whose blood test during screening shows a certain type of immune cell (eosinophils) at 150 cells per microlitre or higher
People whose COPD symptom score (CAT score) is 15 or higher at screening
People who are current or former smokers with a smoking history of at least 10 pack-years (a measure of how much someone has smoked over their lifetime)
Who may not be able to join:
People who have another significant lung disease, or whose chest imaging suggests a respiratory condition other than COPD
People who have asthma (including a history of childhood asthma) or a combined asthma-COPD condition
People who have any unstable health condition that could affect their safety or the results of the study
People who have needed treatment for tuberculosis within the 12 months before their second study visit
People who currently have, or have previously had, a cancer diagnosis
People who have been taking macrolide antibiotics for less than 6 months (confirm with trial site)
People who are taking medications that suppress or alter the immune system
People who require high-flow long-term oxygen therapy above 4 litres per minute, or whose blood oxygen levels remain too low even while on long-term oxygen therapy
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 14 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇪 Belgium
🇧🇬 Bulgaria
🇨🇴 Colombia
🇩🇰 Denmark
🇫🇷 France
🇬🇷 Greece
Hong Kong
🇭🇺 Hungary
🇮🇱 Israel
🇯🇵 Japan
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇪 Peru
🇷🇴 Romania
🇿🇦 South Africa
🇸🇪 Sweden
🇹🇭 Thailand
Turkey (Türkiye)
🇺🇸 United States
🇻🇳 Vietnam
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Annualised rate of moderate or severe COPD exacerbations
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.